BridgeBio Pharma, Inc. Stock 12‑Month Price Target Cut to $109.44, Implies 55% Upside

BridgeBio Pharma's average price target was reduced from $110.47 to $109.44 by 18 analysts, with a range of $88 to $156. This implies a 55% upside from the Oct. 29 closing price. The consensus rating remains 'Buy' among 23 analysts.

Original reporting
Published Oct 30, 2026, 7:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BridgeBio Pharma, Inc. Stock 12‑Month Price Target Cut to $109.44, Implies 55% Upside — source image
Decision brief

The 30-second read

$BBIOBearishLow
01

Why it matters

The new consensus target reflects a slight downgrade but retains a buy rating, indicating mixed sentiment.

02

Market read

Analyst target revisions are a routine driver of short‑term price moves in biotech equities.

03

What to watch

Underlying pipeline progress or upcoming data releases could offset the modest target reduction.

Relevance 5/10Novelty 4/10Timing: today

Background

BridgeBio Pharma is a clinical‑stage biotech focused on genetics‑driven diseases. Analyst coverage is relatively concentrated.

Company-level read

Ticker impact

$BBIOBearishMedium confidence
Context

Analyst consensus price target for BridgeBio Pharma was lowered to $109.44, down from $110.47, indicating a fresh downgrade in expectations.

Expected impact

likely downside as investors price in the lower target

Evidence & confidence

A fresh analyst price‑target reduction is new information that can trigger short‑term selling pressure.

Market effects

May slightly temper sentiment toward biotech stocks reliant on analyst coverage.

Limited to U.S. markets where BBIO trades.

Minimal

Counterpoint

The target cut is modest; the stock still shows 55% upside from current price, suggesting potential for a rebound.

Key entities

  • BridgeBio Pharma, Inc.

    Clinical‑stage biotech company whose price target was adjusted.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.